## DANSHENOLS A AND B, NEW ALDOSE REDUCTASE INHIBITORS FROM THE ROOT OF SALVIA MILTIORHIZA BUNGE

Rena KASIMU, Purusotam BASNET, Yasuhiro TEZUKA, Shigetoshi KADOTA,\* and Tsuneo NAMBA

Research Institute for Wakan-Yaku (Traditional Sino-Japanese Medicines), Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930-01, Japan

Two new abietane-type diterpenoids, danshenols A (1) and B (2), were isolated from an MeOH extract of *Salvia miltiorhiza* BUNGE, and their structures determined by chemical and spectroscopic methods including the 2D NMR technique. Danshenol A (1) showed strong inhibitory activity against aldose reductase isolated from the eye lens of rats.

**KEY WORDS** danshenol; abietane-type diterpene; aldose reductase inhibitor; *Salvia miltiorhiza*; Lamiaceae

The traditional Chinese medicine "Dan-Shen (丹参)" is made from the dried root of *Salvia miltiorhiza* BUNGE (Lamiaceae) and is used to treat hematological abnormalities, heart disease, menstrual disorders, miscarriage, hepatitis, and swelling. Moreover, it has been reported that the MeOH extract of "Dan-Shen" shows strong inhibitory activity against aldose reductase. Thus, as one of our studies on drugs effective for the treatment of diabetes and/or diabetic complications, we examined the aldose reductase-inhibitory constituents of *S. miltiorhiza* and isolated two new abietane-type diterpenes, danshenol A (1) and danshenol B (2), along with four known ones, dihydrotanshinone  $I^{4,5}$  (3), cryptotanshinone  $I^{4,6}$  (4), tanshinone  $I^{4,7}$  (6). In this communication, we report the isolation and structure elucidation of the new compounds, as well as their inhibitory activity against aldose reductase.

Chopped root (8 kg) of *S. miltiorhiza* was extracted successively with hot water and MeOH to give a water extract and an MeOH extract, respectively. The MeOH extract, which showed inhibitory activity against aldose reductase, was treated with EtOAc to give EtOAc-soluble and EtOAc-insoluble fractions, and then the EtOAc-soluble fraction was divided into CHCl<sub>3</sub>-soluble and CHCl<sub>3</sub>-insoluble fractions. The CHCl<sub>3</sub>-soluble fraction was then separated by a combination of silica gel column chromatography (hexane-CHCl<sub>3</sub> solvent system) and preparative TLC (EtOAc-benzene solvent system) procedures to give two new abietane-type diterpenes, danshenol A (1, 7 mg) and danshenol B (2, 23 mg), along with four known compounds, dihydrotanshinone I (3, 17 mg), cryptotanshinone (4, 35 mg), tanshinone I (5, 22 mg), and tanshinone IIA (6, 672 mg).

\* To whom correspondence should be addressed.

© 1997 Pharmaceutical Society of Japan

March 1997 565

Danshenol A<sup>8)</sup> (1) was obtained as dark yellow needles, mp 182°C (MeOH), and showed  $[\alpha]_D$  -136.4° (CHCl<sub>3</sub>). Its molecular formula was determined by HR-MS measurement to be  $C_{21}H_{20}O_4$  (m/z 336), which was  $C_3H_6O$  more than that of dihydrotanshinone I (3). The <sup>1</sup>H- and <sup>13</sup>C-NMR spectra of 1 were partially similar to those of 3, and analyses of the <sup>1</sup>H-<sup>1</sup>H and <sup>1</sup>H-<sup>13</sup>C COSY spectra of 1 indicated the presence of the same A-, B-, and D-rings as 3 (A-ring:  $\delta_H$  9.03, d, J = 9 Hz,  $\delta_C$  125.8, C1-H;  $\delta_H$  7.52, dd, J = 9, 6.5 Hz,  $\delta_C$  126.7, C2-H;  $\delta_H$  7.44, d, J = 6.5 Hz,  $\delta_C$  128.5, C3-H;  $\delta_H$  2.73, s,  $\delta_C$  20.1, C18-H<sub>3</sub>; B-ring:  $\delta_H$  8.10, dd, J = 9, 1 Hz,  $\delta_C$  125.5, C6-H;  $\delta_H$  7.80, d, J = 9 Hz,  $\delta_C$  120.1, C7-H; D-ring:  $\delta_H$  1.45, d, J = 6.5 Hz,  $\delta_C$  18.0, C17-H<sub>3</sub>;  $\delta_H$  3.67, dqd, J = 9.5, 9, 6.5 Hz,  $\delta_C$  34.5, C15-H;  $\delta_H$  4.00 and 5.00, both dd, J = 9.5, 9 Hz,  $\delta_C$  81.4, C16-H<sub>2</sub>). In addition, they showed signals due to a methylene ( $\delta_H$  3.07 and 3.30, both d, J = 12.5 Hz,  $\delta_C$  57.3, C20-H<sub>2</sub>) and a methyl ( $\delta_H$  1.98, s,  $\delta_C$  32.1, C22-H<sub>3</sub>) group, and the <sup>13</sup>C-NMR spectrum of 1 revealed the presence of an oxygenbearing quaternary carbon ( $\delta_C$  79.2) and a low-field shift of two carbonyl carbons (1:  $\delta_C$  204.8, 196.1; 3:  $\delta_C$  175.8, 185.3). These data suggested that danshenol A was an abietane-type diterpene with an additional C3 unit (CH<sub>3</sub>-CO-CH<sub>2</sub> grouping) on the C-ring, which was supported by the fact that Eu(DPM)<sub>3</sub><sup>9)</sup> caused a *retro*-aldol reaction to give 3.

The location of the additional C3 unit was determined by the HMBC spectrum. The quaternary carbons C-4 ( $\delta_C$  135.2), C-5 ( $\delta_C$  134.9), and C-10 ( $\delta_C$  131.0) were assigned based on the long-range correlations with 2-H, 6-H, and 18-H<sub>3</sub>, with 1-H, 3-H, 7-H, and 18-H<sub>3</sub>, and with 2-H and 6-H, respectively. Similarly, the quaternary carbons C-8 ( $\delta_C$  120.4), C-9 ( $\delta_C$  141.3), C-13 ( $\delta_C$  113.6), and C-14 ( $\delta_C$  171.3) were correlated with 6-H, with 1-H and 7-H, with 15-H, 16-H<sub>2</sub>, and 17-H<sub>3</sub>, and with 7-H and 16-H<sub>2</sub>, respectively. On the other hand, the carbon C-9 ( $\delta_C$  141.3) also showed long-range correlations with the methylene protons (20-H<sub>2</sub>) on the additional C3 unit. Thus the location of the additional C3 unit was determined to be at C-11. From these and other long-range correlations observed in the HMBC spectrum, the planar structure of danshenol A was concluded to be 1.

In the difference NOE experiments, irradiation of 17-H<sub>3</sub> caused the NOE increase at 22-H<sub>3</sub> and *vice versa*, indicating that these methyls were in *cis* relation. On the other hand, dihydrotanshinone I (3) prepared through the *retro*-aldol reaction by Eu(DPM)<sub>3</sub> showed  $[\alpha]_D^{25}$  -146.6° (CHCl<sub>3</sub>, c = 0.09) (lit.<sup>4)</sup>  $[\alpha]_D^{24}$  -328°, CHCl<sub>3</sub>, c = 0.11), indicating that the configuration at C-15 is R. Thus the structure of danshenol A, including the absolute stereochemistry, was determined to be 1.<sup>10</sup>)

Danshenol B<sup>11)</sup> (2), yellow needles, mp 176°C (MeOH),  $[\alpha]_D$  -131.6° (CHCl<sub>3</sub>), showed the molecular ion at m/z 354 and its molecular formula was determined as  $C_{22}H_{26}O_4$  by HR-MS measurement. The <sup>1</sup>H-NMR spectrum of 2 was partially similar to that of cryptotanshinone (4) and showed the signals of three coupled methylenes ( $\delta_H$ , 3.41, 1H, ddd, J = 17.5, 9, 5 Hz, 1-H; 3.12, 1H, dt, J = 17.5, 5 Hz, 1-H; 1.87 and 1.70, each 1H, m, 2-H<sub>2</sub>; 1.69, 2H, m, 3-H<sub>2</sub>), two coupled aromatic protons ( $\delta_H$  7.49, 1H, d, J = 8.5 Hz, 6-H; 7.41, 1H, d, J = 8.5 Hz, 7-H), a CH<sub>3</sub>-CH-CH<sub>2</sub>-O grouping ( $\delta_H$  1.39, 3H, d, J = 7 Hz, 17-H<sub>3</sub>; 4.90 and 4.30, each 1H, t, J = 8.5 Hz, 16-H<sub>2</sub>; 3.58, 1H, tq, J = 8.5, 7 Hz, 15-H), and two singlet methyls ( $\delta_H$  1.34 and 1.30, each 3H, s, 18-H<sub>3</sub> and 19-H<sub>3</sub>). In addition, the signals due to the CH<sub>3</sub>-CO-CH<sub>2</sub> grouping in the <sup>1</sup>H-NMR spectrum of 1 were also observed ( $\delta_H$  3.10 and 2.83, each 1H, d, J = 12.5 Hz, 2.06, 3H, s). Thus 2 was assumed to have the same modified C-ring as 1, which was confirmed by the <sup>1</sup>H-<sup>1</sup>H COSY, <sup>1</sup>H-<sup>13</sup>C COSY, and HMBC spectra. On the other hand, the stereochemistry of danshenol B, including the absolute one, was determined to be 2, <sup>10</sup> based on the facts that in the difference NOE experiments NOEs were observed between 17-H<sub>3</sub> and 22-H<sub>3</sub> and that Eu(DPM)<sub>3</sub> caused a *retro*-aldol reaction to give 4 ( $[\alpha]_D^{25}$  -56.8°, CHCl<sub>3</sub>, c = 0.09) (lit.4)  $[\alpha]_D^{24}$  -79.9°, CHCl<sub>3</sub>, c = 0.18).

The inhibitory activities of **1-6** against aldose reductase isolated from the eye lens of rats<sup>12)</sup> were compared with those of quercetin, a natural aldose reductase inhibitor, and epalrestat, a strong aldose reductase inhibitor in clinical use, with or without bovine serum albumin (BSA). The IC<sub>50</sub> values of **1-6**, quercetin, and epalrestat without BSA were 0.10, 1.75, 1.19, 10.0, 4.80, 1.14, 5.6, and 0.038  $\mu$ M, respectively, while those with 1% BSA were 29.1, 32.3, 58.1, 67.3, 39.6, 37.8,

566 Vol. 45, No. 3

39.8, and  $0.86 \mu M$ , respectively. Further studies on these and other constituents are now in progress and will be reported elsewhere.

## REFERENCES AND NOTES

- Pharmacopoeia Committee of the Health Ministry of the People's Republic of China (ed.), "Pharmacopoeia of People's Republic of China," Vol. 1, Guangdong Scientific Technologic Publisher, Guangdong, 1995, pp.62-63; Chiang Su New Medicinal College (ed.), "Dictionary of Chinese Crude Drugs," Shanghai Scientific Technologic Publisher, Shanghai, 1977, pp. 478-482; Namba T., "The Encyclopedia of Wakan-Yaku (Traditional Sino-Japanese Medicines) with Color Pictures," Vol. I, Hoikusha Publishing Co., Ltd., Osaka, 1993, pp. 24-25.
- 2) Zhang J., Zhou Y., China Journal of Chinese Materia Medica, 14, 557-559 (1989).
- 3) Our recent publications on this line are the following: Basnet P., Kadota S., Pandey R. R., Takahashi T., Kojima Y., Shimizu M., Takata Y., Kobayashi M., Namba T., *J. Trad. Med.*, **12**, 109-117 (1995); Basnet P., Kadota S., Hase K., Namba T., *Chem. Pharm. Bull.*, **43**, 1558-1564 (1995).
- 4) Onitsuka M., Fujiu M., Shinma N., Maruyama H. B., Chem. Pharm. Bull., 31, 1670-1675 (1983).
- 5) Ikeshiro Y., Hashimoto I., Iwamoto Y., Mase I., Tomita Y., Phytochemistry, 30, 2791-2792 (1991).
- 6) Ikeshiro Y., Mase I., Tomita Y., *Phytochemistry*, **28**, 3139-3141 (1989); Tomita Y., Ikeshiro Y., *J. Chem. Soc.*, *Chem. Commun.*, **1987**, 1311-1313.
- 7) Luo H.-W., Wu B.-J., Wu M.-Y., Yong Z.-G., Niwa M., Hirata Y., Phytochemistry, 24, 815-817 (1985).
- 8) Danshenol A (1): dark yellow needles, mp 182°C (MeOH),  $[\alpha]_D^{25}$  -136.4° (CHCl<sub>3</sub>, c = 0.07). UV  $\lambda_{max}$  (MeOH) nm (log  $\epsilon$ ): 231 (4.32), 265 (sh), 275 (4.19), 287 (4.04), 299 (3.90), 343 (sh), 356 (3.42), 372 (sh), 403 (3.12). IR  $\nu_{max}$  (KBr) cm<sup>-1</sup>: 3350, 1600, 1380, 1160, 1170, 910. EI-MS m/z: 336 (M<sup>+</sup>), 296, 279, 268, 253. HR-MS: 336.1395 (C<sub>21</sub>H<sub>20</sub>O<sub>4</sub> requires 336.1361). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 204.8 (s, C-21), 196.1 (s, C-12), 171.3 (s, C-14), 141.3 (s, C-9), 135.2 (s, C-4), 134.9 (s, C-5), 131.0 (s, C-10), 128.5 (d, C-3), 126.7 (d, C-2), 125.8 (d, C-1), 125.5 (d, C-6), 120.4 (s, C-8), 120.1 (d, C-7), 113.6 (s, C-13), 81.4 (t, C-16), 79.3 (s, C-11), 57.3 (t, C-20), 34.5 (d, C-15), 32.1 (q, C-22), 20.1 (q, C-18), 18.0 (q, C-17).
- 9) We tried to determine the relative stereochemistry between C11-OH and 15-H or 17-H<sub>3</sub> through an Eu(DPM)<sub>3</sub>-induced shift study, but the reagent caused a *retro*-aldol reaction.
- 10) The possibility that danshenols A (1) and B (2) were artifacts has been excluded, because we did not use acetone in the isolation procedure; the TLC analysis (AcOEt-benzene=13:87) of the MeOH extract indicated the presence of 1 (Rf, 0.24) and 2 (Rf, 0.33); and the treatment of dihydrotanshinone I (3) with silica gel in refluxing acetone resulted in recovery of 3.
- 11) Danshenol B (2): yellow needles, mp 176°C (MeOH),  $[α]_D^{25}$  -131.6° (CHCl<sub>3</sub>, c = 0.10). UV  $λ_{max}$  (MeOH) nm (log ε): 214 (4.18), 230 (4.10), 275 (4.06), 287 (3.84), 299 (3.90), 343 (sh), 356 (3.42), 372 (sh), 403 (3.12). IR  $ν_{max}$  (KBr) cm<sup>-1</sup>: 3350, 1620, 1460, 1260, 1175, 1085, 1020, 790. EI-MS m/z: 354 (M<sup>+</sup>), 311, 296, 268, 253. HR-MS: 354.1866 ( $C_{22}H_{26}O_4$  requires 354.1831). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ: 205.1 (s, C-21), 196.0 (s, C-12), 171.6 (s, C-14), 140.9 (s, C-9), 137.3 (s, C-5), 132.6 (s, C-10), 127.3 (d, C-6), 122.2 (d, C-7), 120.3 (s, C-8), 112.5 (s, C-13), 81.5 (t, C-16), 79.6 (s, C-11), 54.8 (t, C-20), 38.7 (t, C-3), 35.3 (s, C-4), 34.7 (q, C-18), 34.4 (d, C-15), 32.2 (q, C-22), 31.7 (q, C-19), 29.2 (t, C-1), 19.9 (t, C-2), 17.9 (q, C-17).
- 12) Terashima S., Shimizu M., Nakayama H., Ishikura M., Ueda Y., Imai K., Suzui A., Morita N., Chem. Pharm. Bull., **38**, 2733-2736 (1990); Kador P. F., Sharpless N. E., Biophys. Chem., **8**, 81-85 (1978).
- 13) Varma S. D., Mikuni I., Kinoshita J. H., Science, 188, 1215-1216 (1975).
- 14) Terashima H., Hama K., Yamamoto R., Tsuboshima M., Kikkawa R., Hatanaka I., Shigeta Y., J. Pharmacol. Exp. Ther., 229, 226-230 (1984).

(Received January 9, 1997; accepted February 13, 1997)